104 related articles for article (PubMed ID: 22465063)
1. Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: results from a 12-week, open-label pilot study in multiple sclerosis patients.
Moberly JB; Ford DM; Zahir H; Chen S; Mochizuki T; Truitt KE; Vollmer TL
J Neuroimmunol; 2012 May; 246(1-2):100-7. PubMed ID: 22465063
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological modulation of peripheral T and B lymphocytes by a selective sphingosine 1-phosphate receptor-1 modulator.
Moberly JB; Rohatagi S; Zahir H; Hsu C; Noveck RJ; Truitt KE
J Clin Pharmacol; 2012 Jul; 52(7):996-1006. PubMed ID: 21566200
[TBL] [Abstract][Full Text] [Related]
3. Use of an exposure-response model to aid early drug development of an oral sphingosine 1-phosphate receptor modulator.
Rohatagi S; Zahir H; Moberly JB; Truitt KE; Inaba S; Shimozato T; Carrothers TJ
J Clin Pharmacol; 2009 Jan; 49(1):50-62. PubMed ID: 18948412
[TBL] [Abstract][Full Text] [Related]
4. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
[TBL] [Abstract][Full Text] [Related]
5. Impact of sphingosine 1-phosphate modulation on immune outcomes.
Pinschewer DD; Brinkmann V; Merkler D
Neurology; 2011 Feb; 76(8 Suppl 3):S15-9. PubMed ID: 21339486
[TBL] [Abstract][Full Text] [Related]
6. Local inactivation of sphingosine 1-phosphate in lymph nodes induces lymphopenia.
Sensken SC; Nagarajan M; Bode C; Gräler MH
J Immunol; 2011 Mar; 186(6):3432-40. PubMed ID: 21289303
[TBL] [Abstract][Full Text] [Related]
7. Fingolimod for the treatment of relapsing multiple sclerosis.
Jeffery DR; Markowitz CE; Reder AT; Weinstock-Guttman B; Tobias K
Expert Rev Neurother; 2011 Feb; 11(2):165-83. PubMed ID: 21158700
[TBL] [Abstract][Full Text] [Related]
8. Purification and identification of activating enzymes of CS-0777, a selective sphingosine 1-phosphate receptor 1 modulator, in erythrocytes.
Yonesu K; Kubota K; Tamura M; Inaba S; Honda T; Yahara C; Watanabe N; Matsuoka T; Nara F
J Biol Chem; 2011 Jul; 286(28):24765-75. PubMed ID: 21613209
[TBL] [Abstract][Full Text] [Related]
9. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.
Mehling M; Brinkmann V; Antel J; Bar-Or A; Goebels N; Vedrine C; Kristofic C; Kuhle J; Lindberg RL; Kappos L
Neurology; 2008 Oct; 71(16):1261-7. PubMed ID: 18852441
[TBL] [Abstract][Full Text] [Related]
10. Future clinical challenges in multiple sclerosis: Relevance to sphingosine 1-phosphate receptor modulator therapy.
Hohlfeld R; Barkhof F; Polman C
Neurology; 2011 Feb; 76(8 Suppl 3):S28-37. PubMed ID: 21339488
[TBL] [Abstract][Full Text] [Related]
11. Fingolimod: a novel immunosuppressant for multiple sclerosis.
Brown BA; Kantesaria PP; McDevitt LM
Ann Pharmacother; 2007 Oct; 41(10):1660-8. PubMed ID: 17785617
[TBL] [Abstract][Full Text] [Related]
12. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study.
O'Connor P; Comi G; Montalban X; Antel J; Radue EW; de Vera A; Pohlmann H; Kappos L;
Neurology; 2009 Jan; 72(1):73-9. PubMed ID: 19122034
[TBL] [Abstract][Full Text] [Related]
13. The sphingosine-1-phosphate receptor: A novel therapeutic target for multiple sclerosis and other autoimmune diseases.
Mao-Draayer Y; Sarazin J; Fox D; Schiopu E
Clin Immunol; 2017 Feb; 175():10-15. PubMed ID: 27890706
[TBL] [Abstract][Full Text] [Related]
14. FTY720 on the way from the base camp to the summit of the mountain: relevance for remyelination.
Kipp M; Amor S
Mult Scler; 2012 Mar; 18(3):258-63. PubMed ID: 22383435
[TBL] [Abstract][Full Text] [Related]
15. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
Singer B; Ross AP; Tobias K
Int J Clin Pract; 2011 Aug; 65(8):887-95. PubMed ID: 21679286
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and disposition of CS-0777, a sphingosine 1-phosphate receptor modulator, in rats and monkeys.
Inaba S; Ikeda T; Goto M; Tanaka H; Takahashi M; Iwabuchi H; Izumi T
Xenobiotica; 2015; 45(12):1063-80. PubMed ID: 26084376
[TBL] [Abstract][Full Text] [Related]
17. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.
Mehling M; Lindberg R; Raulf F; Kuhle J; Hess C; Kappos L; Brinkmann V
Neurology; 2010 Aug; 75(5):403-10. PubMed ID: 20592255
[TBL] [Abstract][Full Text] [Related]
18. Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor.
Walzer T; Chiossone L; Chaix J; Calver A; Carozzo C; Garrigue-Antar L; Jacques Y; Baratin M; Tomasello E; Vivier E
Nat Immunol; 2007 Dec; 8(12):1337-44. PubMed ID: 17965716
[TBL] [Abstract][Full Text] [Related]
19. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
Dev KK; Mullershausen F; Mattes H; Kuhn RR; Bilbe G; Hoyer D; Mir A
Pharmacol Ther; 2008 Jan; 117(1):77-93. PubMed ID: 17961662
[TBL] [Abstract][Full Text] [Related]
20. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
Lee CW; Choi JW; Chun J
Arch Pharm Res; 2010 Oct; 33(10):1567-74. PubMed ID: 21052934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
